EUVIMEDEUVIMED entdecken
Vergleichsstudie

Clinical outcomes and cost-utility analysis of GKRS plus TKIs versus TKIs in patients with EGFR-mutant lung adenocarcinoma and brain metastases: a Markov decision model

Szu-Hao Andrew Liu, Cheng-Chia Lee, Huai-Che Yang, Wei-Lun Huang, Yu-Hsien Huang, Wen-Yuh Chung, Hon-Yi Shi

Journal of Neurosurgery · 2025

DOI: 10.3171/2024.7.jns24310 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Neurosurgery, 2025. Verfasst von Szu-Hao Andrew Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Neurosurgery, Kaohsiung Veterans General Hospital, Kaohsiung. Hauptthemen laut MEDLINE: Brain Neoplasms, Radiosurgery, Protein Kinase Inhibitors, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE This study focuses on epidermal growth factor receptor–mutated lung adenocarcinoma, known for frequent brain metastasis. It aimed to compare the clinical outcomes and cost-effectiveness of combining Gamma Knife radiosurgery (GKRS) with tyrosine kinase inhibitors (TKIs) (GKRS+TKI group) versus TKIs alone (TKI group) for the treatment of patients with newly diagnosed brain metastasis in this condition. METHODS Study characteristics of the two groups were matched using inverse probability of treatment weighting (IPTW). In the incremental cost-utility ratio (ICUR) model, a healthcare provider perspective, a 1-month cycle length, a 5-year time horizon, and a discount rate of 2% per year for both effectiveness and costs were adopted. Probabilistic and one-way sensitivity analyses were also conducted to demonstrate the robustness of the findings. Statistical analysis was performed using IBM SPSS version 23.0, and cost-effectiveness analysis was conducted using TreeAge Pro software. RESULTS After applying IPTW, the GKRS+TKI group included 205 patients, and the TKI group consisted of 102 patients, with no statistically significant differences in whole confounders. The GKRS+TKI group demonstrated significantly prolonged median progression-free survival (37.5 months vs 10.6 months, p < 0.001) and median overall survival (55.1 months vs 30.8 months, p < 0.001) compared with the TKI group. The GKRS plus TKI strategy achieved an ICUR of $30,532.25 per quality-adjusted life year relative to the TKIs at the willingness-to-pay threshold of US$33,059 (Taiwan’s per capita gross domestic product). CONCLUSIONS The use of GKRS plus TKIs not only reduces disease recurrence and improves prognosis but also demonstrates a higher level of cost-effectiveness. These findings offer valuable guidelines for clinicians and inform healthcare authorities in optimizing resource allocation for improved medical care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsRadiosurgeryProtein Kinase InhibitorsLung NeoplasmsAdenocarcinoma of LungHumansCost-Benefit AnalysisMarkov ChainsMaleFemaleMiddle AgedErbB ReceptorsAgedMutationTreatment OutcomeCombined Modality Therapy

Stichwörter der Autor:innen

Gamma Knife stereotactic radiosurgeryMarkov modelcost-utility analysisepidermal growth factor receptortyrosine kinase inhibitors

Substanzen

Protein Kinase InhibitorsErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • 1Department of Neurosurgery, Kaohsiung Veterans General Hospital, Kaohsiung.
  • 2Department of Pharmacy and Master Program, Tajen University, Pingtung.
  • 3School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung.
  • 4Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei.
  • 5School of Medicine, National Yang Ming Chiao Tung University, Taipei.
  • 6Department of Radiation Oncology, Kaohsiung Veterans General Hospital, Kaohsiung.

Zitieren

APA

Liu, S. A., Lee, C. C., Yang, H. C., Huang, W. L., Huang, Y. H., Chung, W. Y., & Shi, H. Y. (2025). Clinical outcomes and cost-utility analysis of GKRS plus TKIs versus TKIs in patients with EGFR-mutant lung adenocarcinoma and brain metastases: a Markov decision model. Journal of Neurosurgery. https://doi.org/10.3171/2024.7.jns24310

Vancouver

Liu SA, Lee CC, Yang HC, Huang WL, Huang YH, Chung WY, et al. Clinical outcomes and cost-utility analysis of GKRS plus TKIs versus TKIs in patients with EGFR-mutant lung adenocarcinoma and brain metastases: a Markov decision model. Journal of Neurosurgery. 2025. doi:10.3171/2024.7.jns24310

BibTeX
@article{Liu2025,
  author = {Liu, Szu-Hao Andrew and Lee, Cheng-Chia and Yang, Huai-Che and Huang, Wei-Lun and Huang, Yu-Hsien and Chung, Wen-Yuh and Shi, Hon-Yi},
  title = {Clinical outcomes and cost-utility analysis of GKRS plus TKIs versus TKIs in patients with EGFR-mutant lung adenocarcinoma and brain metastases: a Markov decision model},
  journal = {Journal of Neurosurgery},
  year = {2025},
  doi = {10.3171/2024.7.jns24310}
}
Kostenlos starten →